12,721 Moderna, Inc. $MRNA Shares Bought by Illinois Municipal Retirement Fund

by · The Markets Daily

Illinois Municipal Retirement Fund grew its position in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) by 12.3% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 115,726 shares of the company’s stock after purchasing an additional 12,721 shares during the period. Illinois Municipal Retirement Fund’s holdings in Moderna were worth $22,285,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the company. Costello Asset Management INC boosted its stake in shares of Moderna by 7.3% in the third quarter. Costello Asset Management INC now owns 966 shares of the company’s stock valued at $186,000 after purchasing an additional 66 shares during the period. Physician Wealth Advisors Inc. grew its holdings in Moderna by 8.3% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 886 shares of the company’s stock valued at $171,000 after purchasing an additional 68 shares in the last quarter. Fortitude Family Office LLC increased its stake in Moderna by 53.1% during the 3rd quarter. Fortitude Family Office LLC now owns 222 shares of the company’s stock worth $43,000 after buying an additional 77 shares during the period. Lido Advisors LLC lifted its holdings in Moderna by 0.5% in the 3rd quarter. Lido Advisors LLC now owns 16,605 shares of the company’s stock worth $3,198,000 after buying an additional 83 shares in the last quarter. Finally, TD Waterhouse Canada Inc. lifted its holdings in Moderna by 2.6% in the 2nd quarter. TD Waterhouse Canada Inc. now owns 3,388 shares of the company’s stock worth $246,000 after buying an additional 85 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on MRNA shares. Barclays upped their price objective on shares of Moderna from $48.00 to $125.00 and gave the company an “equal weight” rating in a research report on Monday, August 24th. Piper Sandler reaffirmed an “overweight” rating and set a $305.00 target price (up from $230.00) on shares of Moderna in a research report on Monday. JPMorgan Chase & Co. boosted their price target on Moderna from $40.00 to $77.00 and gave the stock an “underweight” rating in a research note on Friday, August 21st. Bradesco Corretora raised Moderna to an “outperform” rating in a report on Friday, August 28th. Finally, TD Cowen reissued a “buy” rating on shares of Moderna in a report on Wednesday, October 21st. Six research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $113.75.

View Our Latest Stock Report on MRNA

Key Moderna News

Here are the key news stories impacting Moderna this week:

  • Positive Sentiment: Moderna reported third-quarter revenue of about $1.3 billion, up 29% year over year and ahead of expectations, and raised its 2026 revenue-growth outlook to 15%–25%. Lower costs and respiratory-vaccine gains also supported the improved outlook. Why is Moderna stock soaring today?
  • Positive Sentiment: Investors also have a potential longer-term catalyst in personalized cancer vaccine intismeran. Phase 3 results reportedly showed a 42% reduction in melanoma recurrence or death, and Moderna is targeting an FDA filing by year-end 2026, which could lead to a decision in 2027. Can Moderna’s first cancer therapy win FDA approval in 2027?
  • Neutral Sentiment: Moderna is scheduled to present at the Jefferies Global Health Care Conference on November 18. The event could provide updates, but the announcement itself does not change the company’s outlook. Moderna to present at upcoming conference
  • Negative Sentiment: Despite the earnings beat, nearly all of Moderna’s revenue still comes from COVID-related products, leaving investors focused on the challenge of building durable sales beyond the pandemic market. That concern may weigh more heavily after the stock’s sharp recent run. Moderna’s Q3 numbers may not be enough to make the stock a buy
  • Negative Sentiment: Valuation is another headwind: Goldman Sachs raised its price target but kept a neutral rating, while a separate analysis put fair value well below the prevailing share price. Brookline also made modest reductions to its long-term earnings estimates, despite maintaining a Buy rating.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $250.83 on Wednesday. Moderna, Inc. has a twelve month low of $22.28 and a twelve month high of $280.80. The company has a current ratio of 3.62, a quick ratio of 3.47 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $101.49 billion, a price-to-earnings ratio of -35.33 and a beta of 1.16. The business has a 50 day simple moving average of $196.68 and a 200-day simple moving average of $93.60.

Moderna (NASDAQ:MRNA – Get Free Report) last announced its quarterly earnings data on Friday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $1.48. The firm had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $890.25 million. Moderna had a negative return on equity of 25.79% and a negative net margin of 110.46%. The firm’s revenue for the quarter was up 29.2% on a year-over-year basis. During the same period last year, the business posted ($0.51) earnings per share. As a group, equities research analysts expect that Moderna, Inc. will post -5.69 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Shannon Klinger sold 3,471 shares of the stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total transaction of $485,766.45. Following the sale, the insider owned 74,129 shares in the company, valued at $10,374,353.55. This represents a 4.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 39,145 shares of the company’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $220.72, for a total value of $8,640,084.40. Following the transaction, the president directly owned 1,636,565 shares of the company’s stock, valued at $361,222,626.80. This trade represents a 2.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 197,251 shares of company stock valued at $33,875,904. Company insiders own 10.80% of the company’s stock.

About Moderna

(Free Report)

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

Featured Articles